Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

First International Summit on Interventional Pharmacoeconomics

Mark J. Ratain, MD, on Chronic Lymphocytic Leukemia: Making a Case for Low-Dose Ibrutinib

Mark J. Ratain, MD, of the University of Chicago, talks about why ibrutinib—which can lead to cardiotoxicities—should be studied at a lower dose for patients with chronic lymphocytic leukemia. Data suggest a reduced dose may prevent dose interruption due to adverse events and may have a better therapeutic index.

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

May

Today In Oncology

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

Related Videos

Mark J. Ratain, MD, on Chronic Lymphocytic Leukemia: Making a Case for Low-Dose Ibrutinib

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

FDA Approves Atezolizumab for Adjuvant Treatment of MRD-Positive MIBC

Sigmoidoscopy Reduces CRC Incidence Rates in Men in Norwegian Screening Study

Early Ovarian Cancer Minimally Invasive Surgery, Intraoperative Capsule Rupture, and Survival

Local Salvage Therapy for Post-Radiotherapy Local Recurrence of Prostate Cancer

Study Finds DLBCL Subtype May Have Higher Mortality Risk in Female Patients